South Africa: Positive Interim Findings On New Once-Weekly HIV Treatment Pill

South Africa: Positive Interim Findings On New Once-Weekly HIV Treatment Pill

A new antiretroviral combination pill that is taken only once a week appears to work as well as daily pills at treating HIV. This is according to interim study findings to be presented next week at the AIDS 2026 conference in Rio de Janeiro, Brazil.

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

Gilead, Merck announce new results from ISLEN trials

Gilead and Merck today (Tuesday, July 21) announced  new results from the Phase 3 ISLEND-1(NCT06630286) andISLEND-2(NCT06630299) trials evaluating the treatment responses of people living with HIV with virological suppression who switched from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) or a standard of care oral daily antiretroviral regimen to an investigational once-weekly single-tablet regim…

Gilead and Merck provide HIV data; Dimension Capital announces $800M fund

Gilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral HIV treatment regimen at AIDS 2026, one of the largest ...

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure